Hence, alterations in circulating adiponectin levels, largely thought to be a consequence of changes in the ADIPOQ gene sequence, constitute potential risk for disorders such as obesity [2], insulin resistance [2,3], T2DM [4,5], MS [3], and consequently susceptibility to acquiring atherosclerosis. Here, ADIPOQ is linked to myeloid sarcoma.